Skip to main content

Table 1 Characteristics of studies included in the qualitative systemic review

From: Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis

First author Year Country Participants Race/ethnicity Study design Year range Treatment ROBINS-Id Follow-up (PT/no PT)(years) Primary outcome in the original study
van Sprundel [17] 2005 The Netherlands (M) 148 BRCA1/2 carriers NR RC ~ 2003 CRRM Moderate Mean 3.5 (3.4/3.1) CBC, BCSS, OS, DMR
Kiely [11] 2009 Australia (M)a 1018 BRCA1/2 carriers from high-risk families Caucasian 95%
Asian 1%
Other 2%
Unknown 2%
RC 1997–2008 CRRM Serious Median 11.1
Evans [10] 2013 The UK (M) 698 BRCA1/2 carriers NR PC 1985–2010 CRRM Moderate Median 8.8/7.3 CBC, OS
Metcalfe [18] 2014 Canada (M) 390 patientsc NR RC 1975–2008 CRRM Moderate Median 9.7/8.6 CBC, OS
Heemskerk-Gerritsen [19] 2015 The Netherlands
583 BRCA1/2 carriers NR PC 1980–2011 CRRM Moderate Median 14.3 CBC, OS
Fachinetti [35] 2019 Italy (S) 88 BRCA1/2 carriers NR RC 2006–2016 CRRM NA Median 11.4
Evron [36] 2019 Isreal (M) 162 BRCA1/2 carriers NR PC 2008–2017 CPI Moderate Median 10 CBC, OS
  1. RC retrospective cohort study, PC prospective cohort study, CBC contralateral breast cancer, BCSS breast-cancer specific survival, OS overall survival, DMR distant metastatic recurrence, M multicenter study, S single-center study, NR Not reported, NA Not applicable
  2. aPatients were enrolled in the research program called kConFab (Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer)
  3. bMembers of breast and/or ovarian cancer centers in the HEBON study (nationwide Dutch study on risk assessment and gene–environment interactions)
  4. c336 patients were proved to be BRCA1/2 carriers, 54 were not tested but from family with a BRCA mutation
  5. dSpecific assessment for each signal question in the ROBINS-I tool see: Additional file 1: Method S2